Press Release FeedGet the RSS feed
Menu

Business Wire

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

Business Wire

VANCOUVER, British Columbia, September 16, 2026--AbCellera (Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026 at the Windsor Oceânico Hotel and Congress Center in Rio de Janeiro, Brazil.

Details on AbCellera's oral presentation at IMS are as follows:

Title: Interim Results of a Phase 1/2 Study of ABCL635, a First-in-Class NK3R Monoclonal Antibody for the Treatment of Vasomotor Symptoms
Abstract ID: 16836
Session: Symptoms of Menopause 1
Date and Time: Thursday, October 1 from 8:30 a.m. to 9:30 a.m. GMT-3
Location: Aruba 1, Windsor Oceânico Hotel and Congress Center

AbCellera will present efficacy and safety data from its Phase 2 trial in postmenopausal women with moderate-to-severe vasomotor symptoms (VMS). The abstract can be viewed online here.

About ABCL635

ABCL635 is a potential best-in-class investigational antibody drug for the non-hormonal, long-acting treatment of moderate-to-severe VMS, commonly known as hot flashes, due to menopause. ABCL635 specifically targets NK3R, a clinically validated G protein-coupled receptor (GPCR) expressed on KNDy neurons in the infundibular nucleus of the hypothalamus. ABCL635 is AbCellera's first pipeline program from the GPCR and ion channel platform to advance into the clinic, in July 2025. Additional details are available at www.abcellera.com/pipeline.

The Phase 2 trial of ABCL635 (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled trial in postmenopausal women with moderate-to-severe VMS due to menopause evaluating safety and efficacy of ABCL635.

About VMS

Hot flashes and night sweats, known as VMS, are the most common menopausal symptoms, impacting up to 80% of women. The majority rate their VMS as moderate to severe, characterized by intense feelings of heat that lead to sweating, chills, and interrupted sleep. VMS are the most frequent reason for seeking medical care for menopause. VMS can persist for many years after the final menstrual period, and the impact is felt across many aspects of everyday life, including sleep, concentration, energy and mood, work, social activities, and relationships. It is estimated that approximately 12 million women in the US experience moderate-to-severe VMS, of which more than six million seek treatment.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women's health, immunology, oncology, and more. For more information, please visit www.abcellera.com.

  1. Aerospace & defenseAvionTEq Announces New CTRL Systems Distributorship Ahead of NBAA-BACE 2026VAN NUYS, Calif., October 19, 2026--AvionTEq, a global leader in aviation test equipment and support solutions, announced that it has signed a new agreement as an authorized distributor for CTRL Systems Inc. , an advanced developer of acoustic ultrasound technology. This announcement comes just ahead of the 2026 NBAA Business Aviation Convention & Exhibition (NBAA-BACE), scheduled for October 20–2
  2. AIExtendExtend Introduces Verify, a Document Fraud Detection API that Builds Trust into Document PipelinesVerify detects signs of document tampering and AI-generated fraud, helping businesses trust the documents their AI agents act on and deploy those agents confidently in the real economy. LAS VEGAS, October 19, 2026--Extend today at Money20/20 USA announced Extend Verify , a document fraud detection API
  3. FinanceInstalled Building Products, Inc.Installed Building Products to Increase Existing Term Loan B FacilityCOLUMBUS, Ohio, October 19, 2026--Installed Building Products, Inc. (the "Company" or "IBP") (NYSE: IBP), an industry-leading installer of insulation and complementary building products, announced today that it is seeking to increase its outstanding ~$500 million Term Loan B by $250 million ("Add-On").
  4. AIDream LabsDream Labs Raises $90M Seed to Build the Brain for Everyday RobotsFounded by the former NVIDIA researchers who created DreamZero and World Action Models, Dream Labs launches the first public API for a robot foundation model with more than 20 hardware partners on board SAN FRANCISCO, October 19, 2026--Dream Labs , an AI company building the brain for everyday robots,
  5. Real estateManaged Direct ResponseManaged Direct Response Launches New State-Of-The-Art WebsiteMortgage Direct Mail Leader Continues to Invest in New Technology and Data Innovation IRVINE, Calif., October 19, 2026--Managed Direct Response (MDR), a leading mortgage direct mail marketing company, today announced the launch of its new state-of-the-art website, www.managedmktg.com . The redesigned site gives lenders and other clients a clear view of the company's services, data capabilities and
  6. HealthcareForward Consumer PartnersForward Consumer Partners to Acquire WellyGREENWICH, Conn., October 19, 2026--Forward Consumer Partners ("Forward") today announced that it has signed an agreement to acquire Welly Health PBC, a leading first-aid and bandage brand, from Unilever. Created in 2018 by serial entrepreneur Eric Ryan, Welly is a disruptive consumer healthcare brand built on the premise that cuts and scrapes are proof of a life well-lived. Today, Welly offers a